Selection and prioritization of extracellular tumour-derived genes Candidate extracellular tumour-derived genes were identified using a stepwise filtering and prioritization strategy integrating single-cell transcriptomic analyses, protein subcellular localization annotations, functional dependency data, domain-based functional annotation and literature-based curation (Extended Data Fig. 1a). Publicly available scRNA-seq datasets from human14 and mouse15 PDAC were independently analysed. Within each
FILE – A sign for the U.S. Food and Drug Administration is displayed outside their offices in Silver Spring, Md., Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File) Manuel Balce Ceneta/AP hide caption toggle caption Manuel Balce Ceneta/AP The Food and Drug Administration on Wednesday approved a groundbreaking new drug for advanced pancreatic cancer, offering
The Food and Drug Administration on Wednesday approved Rasonque, a once-daily pill developed by Revolution Medicines to block several forms of the RAS protein — the mutation that drives tumor growth in most pancreatic cancers, and in roughly a quarter of all human cancers overall. For investors like Dr. Danish Nagda, an early shareholder in
The US Food and Drug Administration has approved a treatment for pancreatic cancer that, in clinical trials, nearly doubled the overall survival time for patients. The drug, daraxonrasib, sold under the brand name Rasonque and manufactured by Revolution Medicines, appears to be a breakthrough in treating one of the world’s deadliest cancers. A late-stage clinical
